Accueil   Diary - News   All news Theranexus

Theranexus

 

Lyonbiopole's member Therenaxus is located in Lyon, Theranexus is a clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA) in 2013. It develops drug candidates for the treatment of nervous system diseases. Theranexus identified the key role played by non-neuronal cells (also known as “glial cells”) in the body’s response to psychotropic drugs (which target the neurons). The company is a pioneer in the design and development of drug candidates affecting the interaction between neurons and glial cells. The unique, patented technology used by Theranexus is designed to improve the efficacy of psychotropic drugs already approved and on the market, by combining them with a glial cell modulator. This strategy of combining its innovations with registered drugs means Theranexus can significantly reduce development time and costs and considerably increase the chance of its drugs reaching the market. The proprietary, adaptable Theranexus platform can generate different proprietary drug candidates offering high added-value for multiple indications. Theranexus is listed on the Euronext Growth market in Paris.

 

 

THERANEXUS AND THE COLLEGE DE FRANCE SIGN A RESEARCH AGREEMENT ON ASTROCYTE-NEURON INTERACTIONS

 

Lyon, 15 March 2018 – Theranexus, an innovative biopharmaceutical company in neurological diseases that is pioneering new drug candidates affecting the interaction between neurons and glial cells, has today announced the signature of a three-year research collaboration with the Collège de France, an internationally renowned institution in the field of neurosciences.

This work, looking at the impact of glial cells on neuronal activity, will be led by Dr Nathalie Rouach within the Center for Interdisciplinary Research in Biology (CIRB) headed by Prof Alain Prochiantz. The research will include a doctorate conducted via a CIFRE1 contract (industrial agreement for training through research) with the National Association for Research and Technology (ANRT).

Read the press release

 

THERANEXUS ANNOUNCES A SUCCESSFUL CLINICAL PHARMACOKINETIC STUDY AS
PART OF THE DEVELOPMENT OF ITS DRUG CANDIDATES THN201 AND THN101

 

THERANEXUS, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates acting on the interaction between neurons and glial cells, today announces the results for a clinical pharmacokinetic study of the glial modulator, THN01, a component
of its drug candidates THN201 and THN101. The objective of the study was to determine the dose to be administered to achieve the target plasma exposure and to be able to make progress in the manufacture of pharmaceutical batches for clinical research programmes on the two drug candidates.

Read the press release

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree